Yang Nong, Chief physician, Doctor tutor. Vice president of the Second Peoples Hospital of Hunan Province, chief expert of the National Science and Technology Major Project, Director of Hunan Provincial Clinical Medical Research Center of Respiratory Tumor, Director of Hunan Provincial Key Laboratory of Precision Diagnosis and Treatment of Lung Cancer, Director of the Tropical Tumor Research Institute of Hainan Province, Specially-invited specialists of Hainan Cancer Hospital and Hainan Chengmei Hospital. 
Has been honored with the Sixth National Famous Doctor - Excellent Style and the Seventh National "Good Doctor of the Year" from 2017 to 2023.

Major: Precision immune-targeted therapy for lung cancer/gastrointestinal tumors, difficult recurrent drug resistance; individualized precision therapy for lung cancer brain metastases; early diagnosis of lung nodules and lung cancer; clinical trials of the latest immune/targeted therapeutic agents. 
Has accumulated a large number of successful cases in the field of precision immune-targeted therapy and chemotherapy for lung cancer and gastrointestinal tumors, and is especially experienced in clinical practice for difficult and complicated cases and multi-drug resistance, and conducts clinical research on cutting-edge new anti-cancer drugs. Founded the first clinic specializing in immunotargeted therapy for lung cancer all over China. Has built the largest lung cancer immunotargeted therapy patient service group in Central China, and has managed more than 3,000 long-term surviving lung cancer patients, and has been awarded the national "Good Doctor of the Year" for seven consecutive years from 2017 to 2023.

Precision immune-targeted therapy for lung cancer/gastrointestinal tumors, difficult recurrent drug resistance; individualized precision therapy for lung cancer brain metastases; early diagnosis of lung nodules and lung cancer; clinical trials of the latest immune/targeted therapeutic agents.

Member of Lung Cancer Quality Control Committee of the National Cancer Quality Control Center 
Vice Chairman China Medical Education Association 
Vice Chairman, Oncology Clinical Research Innovation and development Committee, China Medical Education Association 
Director of the Chinese Society of Clinical Oncology and Member of the Specialized Committee on Tumor Immunotherapy, Non-Small Cell Lung Cancer, and Drug Development 
Standing member of Anti-tumor Drugs Committee and Lung Cancer Committee of China Anti-Cancer Association 
Member of Oncology Branch of Chinese Physicians Association 
Chairman of Precision Medicine Specialized Committee of Hunan Anti-cancer Association 
Chairman of Clinical Oncology Branch, Hunan Geriatrics Society

In the past five years, he has published 45 SCI papers as the first or corresponding author in Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology and other international journals, with a cumulative impact factor of 330. Has obtained 4 scientific research achievements above the provincial level, which have been orally reported or exhibited in poster sessions at international conferences such as AACR, ASCO, WCLC and GAP, etc. Has published 46 conference papers, of which 3 are oral presentations, and has been mainly involved in the research and development of 5 original 1.1 new drugs, and has been approved for 3 patents. 
Has participated in the compilation of the Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Primary Lung Cancer, the Chinese Society of Clinical Oncology Expert Consensus on Perioperative Treatment of Early-stage Lung Cancer, the Chinese Medical Association Clinical Guidelines for Lung Cancer, the Ministry of Health Guidelines for the Standardized Diagnosis and Treatment of Common Tumors in Municipal and County Hospitals, the Chinese Expert Consensus for Multidisciplinary Team Diagnosis and Treatment of Lung Cancer, and has also taken part in the formulation of the guiding principles of the CDEs clinical trials of many anticancer drugs. As a principal investigator, he has designed, organized and participated in nearly 300 Phase I-III clinical trials, with more than 30 clinical studies in progress, and has led clinical studies on a number of innovative anti-cancer drugs as Leading PI.